Drug Profile
Research programme: infectious disease monoclonal antibodies - ContraFect/MorphoSys
Latest Information Update: 21 May 2014
Price :
$50
*
At a glance
- Originator ContraFect; MorphoSys
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Bacterial infections; Influenza virus infections; Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 11 Apr 2011 Early research in Bacterial infections in USA (Parenteral)
- 11 Apr 2011 Early research in Influenza virus infections in USA (Parenteral)
- 11 Apr 2011 Early research in Methicillin-resistant Staphylococcus aureus infections in USA (Parenteral)